Diffuse panbronchiolitis—pathophysiology and treatment mechanisms
- 1 September 2001
- journal article
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 18, 83-87
- https://doi.org/10.1016/s0924-8579(01)00403-4
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Improvement of Survival in Patients with Diffuse Panbronchiolitis Treated with Low-dose ErythromycinAmerican Journal of Respiratory and Critical Care Medicine, 1998
- Two-year-outcomes analysis of Crohn's disease treated with rifabutin and macrolide antibioticsJournal of Antimicrobial Chemotherapy, 1997
- Diffuse panbronchiolitis in the United States.American Journal of Respiratory and Critical Care Medicine, 1996
- Interleukin 1β, Tumor Necrosis Factor Alpha, and Interleukin 8 in Bronchoalveolar Lavage Fluid of Patients with Diffuse Panbronchiolitis: A Potential Mechanism of Macrolide TherapyRespiration, 1996
- Long term effect of erythromycin therapy in patients with chronic Pseudomonas aeruginosa infection.Thorax, 1995
- Increase in activated CD8+ cells in bronchoalveolar lavage fluid in patients with diffuse panbronchiolitis.American Journal of Respiratory and Critical Care Medicine, 1995
- Effect of 14-Membered Ring Macrolide Therapy on Chronic Respiratory Tract Infections and Polymorphonuclear Leukocyte Activity.Internal Medicine, 1995
- A Mechanism of Erythromycin Treatment in Patients with Diffuse PanbronchiolitisAmerican Review of Respiratory Disease, 1993
- Neutrophil Attractant/Activation Protein-1 (NAP-1 [Interleukin-8])American Journal of Respiratory Cell and Molecular Biology, 1990
- Diffuse PanbronchiolitisChest, 1983